Key terms
About LYRA
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LYRA news
Apr 17
4:55am ET
Lyra Therapeutics management to meet with Cantor Fitzgerald
Apr 15
7:54am ET
Lyra Therapeutics management to meet with Cantor Fitzgerald
Mar 25
6:42am ET
Lyra Therapeutics price target lowered to $11 from $12 at BofA
Mar 23
10:41am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 22
7:39am ET
Lyra Therapeutics files $300M mixed securities shelf
Mar 22
6:16am ET
Optimistic Buy Rating for Lyra Therapeutics’ LYR-210 Amidst Phase 3 Trial and Market Opportunity
Mar 21
4:10pm ET
Lyra Therapeutics reports Q4 EPS ($1.26), consensus (31c)
Mar 01
4:44pm ET
Lyra Therapeutics Doubles Executive Chair’s Annual Salary
No recent press releases are available for LYRA
LYRA Financials
Key terms
Ad Feedback
LYRA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LYRA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
